US Hematology & Flow Cytometry Market Future Discussed in New Report Published at MarketPublishers.com

February 28, 2012

New research report “Future US Hematology and Flow Cytometry Market Outlook” prepared by Venture Planning Group has been recently published by Market Publishers Ltd. The report reveals that commercialization of innovative products is likely to drive the future growth in the market, and the US will remain the biggest market for hematology.

London, UK (PRWEB) February 28, 2012

Increasing research and commercialization in the field of life sciences such as proteomics, genomics, pharmacogenomics, and stem cell research have resulted in a boosting of high-throughput technologies such as the flow cytometry market. However, several constraints, such as increased equipment cost, are hindering the market growth.

The world hematology market is likely to grow over the forecast period, driven by the development in bench-top high throughput hematology analyzers and in high sensitivity point-of-care (POC) tests. Commercialization of innovative products is also likely to drive the future growth in the market. The US is the biggest market for hematology, contributing around 50% towards the global market share.

New research report “Future US Hematology and Flow Cytometry Market Outlook” prepared by Venture Planning Group has been recently published by Market Publishers Ltd.

Report Details:

Title: Future US Hematology and Flow Cytometry Market Outlook

Published: February, 2012

Pages: 275

Price: US$ 9,500


The report delves into in-depth analysis of the US hematology and flow cytometry markets´ future. Its scope comprises:

  •     key economic, regulatory, demographic, social and technological trends expected to significantly impact the US hematology and flow cytometry market during the next decade;
  •     five-and ten-year volume and sales forecasts for major hematology and flow cytometry tests;
  •     annual placements and installed base estimates for major automated and semiautomated hematology analyzers and flow cytometers;
  •     review of current instrumentation technologies and a feature comparison of over 60 analyzers;
  •     five-and ten-year reagent and instrument sales forecasts;
  •     sales and market shares of top reagent and instrument suppliers;
  •     review of current and emerging technologies, and their potential market applications;
  •     product development opportunities for instruments, consumables, and auxiliary products;
  •     profiles of major current and emerging suppliers;
  •     business opportunities and strategic recommendations for suppliers.

Report Contents:

I. Introduction

Ii. Worldwide Market and Technology Overview

A. Major Routine and Special Hematology Tests

1. Introduction

2. CBC Analysis

    a. Hemoglobin Concentration

    b. Hematocrit Determination

    c. Red Blood Cell Count

    d. Red Cell Indices







    e. Red Cell Size Histograms

    f. Platelets

     Platelet Count

     Platelet Size/MPV


     Automated Systems

3. White Blood Cell Analysis

    a. WBC Count

    b. Five-Partial Differential

     Siemens Advia

     Beckman Coulter VCS

     Sysmex X-Class

     Abbott Cell-DYN Series

     Pattern Recognition Systems

        IRIS Diagnostics

     Comparison of Major Differential Analyzers

4. Reticulocytes

5. Platelet Function Tests

6. Erythrocyte Sedimentation Rate

7. Red Cell Analysis

8. DPG

9. Red Cell Deformability

10. Neutrophil Function Tests

11. Semen Analysis

12. Bone Marrow Analysis

13. Urinalysis

B. Major Flow Cytometry Applications

1. Cell Surface Markers

    a. Lymphocyte Subclassification CD4/CD8

     Instrumentation and Reagent Test Kits

        BD FACS Count

        Beckman Coulter VCS

        T Cells Diagnostics TRAx

    b. Other Cell Markers

2. DNA Content Analysis

3. RNA Content Analysis

4. Chemotherapy Monitoring

5. Cell Cycle Analysis

6. Reticulocytes

More new reports by the publisher can be found at Venture Planning Group page.

# # #

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/2/prweb9234038.htm

Source: prweb

comments powered by Disqus